Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene
-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI). The FFB was an early funding collaborator of Oxford BioMedica's pre-clinical ocular programmes and this award furthers the Company's long-standing relationships with FFB and FFBCRI. The award will support the opening of a second clinical site in Paris, France for the ongoing UshStat® Phase I/IIa study, currently underway in the US.
UshStat® is a novel gene-based treatment for Usher syndrome type 1B, designed and developed by Oxford BioMedica using its proprietary LentiVector® platform technology, and is the third ocular product to enter clinical development under the Company's collaboration with Sanofi (EURONEXT: SAN and NYSE: SNY). In February 2012, Oxford BioMedica initiated an open label, dose escalation Phase I/IIa study in the US led by Professor Richard Weleber at the Oregon Health & Science University's Casey Eye Institute. The ongoing study will enrol up to 18 patients and will evaluate three dose levels for safety, tolerability and aspects of biological activity. Initial safety data from this study are expected in H2 2012.
Oxford BioMedica plans to open the second clinical site at Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts in Paris, France with Professor José-Alain Sahel as Principal Investigator. Subject to receiving regulatory approval, the second clinical site is anticipated to open in early 2013, from which point patients could be treated in parallel at both sites.